ECOG-ACRIN Cancer Research Group

Who should decide which research projects receive federal funding? A new @AACR article examines concerns that proposed OMB grantmaking changes could expand political review of funding decisions & weaken the expert peer review process. More: bit.ly/4fbYne5 #SciencePolicy

What's next for ADC + immunotherapy combos in #UrothelialCancer? @PGrivasMDPhD discusses encouraging subgroup findings from JAVELIN Bladder Medley & highlights EA8231 evaluating sacituzumab govitecan + pembrolizumab after prior immunotherapy. Watch: bit.ly/4aM6MDY

#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more: bit.ly/EA4231 cc: @LLSusa, @lymphomahub

EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: bit.ly/ea8192-trial #blcsm

#ClinicalTrial EA1242/RxFINE-Low, led by @nancychan29 of @Perlmutter_CC, is testing whether #HormoneTherapy plus ribociclib is as effective as chemotherapy followed by hormone therapy plus ribociclib in patients with #BreastCancer. More: bit.ly/ea1242-study

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

#ClinicalTrial EA7211/STRASS 2, led in the US by @kencardonaMD, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: bit.ly/EA7211

EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. Learn more: bit.ly/EA1241 #bcsm

#FindingsFriday: Our latest research round-up is here! Explore findings presented at #ASCO26 and #SNMMI26, including updates from EA6174/STAMP in #MerkelCellCarcinoma, EA1183/FEATURE in metastatic #BreastCancer, and EAF151 in #glioblastoma. Read more: bit.ly/4wyd0jb

#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: bit.ly/mm1oa-ea02-stu…

#ClinicalTrial EAF223/GABLE, led by Dr. Daniel Barboriak of @DukeRadiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: bit.ly/gable-trial

This #SarcomaAwarenessMonth, we're highlighting EA7222, a phase 3 trial evaluating whether adding #Immunotherapy to #Chemotherapy can improve outcomes for patients with advanced soft tissue sarcomas. Learn more: bit.ly/EA7222 cc: @CureSarcoma, @sarcomapatients

#ClinicalTrial EAA181/EQUATE, led by @myelomaMD of @mayoclinic, is testing the use of combination therapy in adult patients with newly diagnosed #MultipleMyeloma. For more information: bit.ly/eaa181equate #MMSM #NDMM

#ClinicalTrial EA2222/PUMP, led by @michael_lidsky, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump

Podcast: @ASCOPost includes updated ECOG-ACRIN STAMP (EA6174) Merkel cell carcinoma trial outcomes, led by @JaniceM10, in #ASCO26 highlights, stating it's what a "trial through a cooperative group can do for rare cancers that don't get as much funding" bit.ly/ASCO26EA

#ClinicalTrial EA8231, led by @MonikaJoshimd & @PGrivasMDPhD, is a phase 3 randomized study exploring a new treatment approach for patients with treatment-refractory, locally-advanced or metastatic #UrothelialCancer. More information here: bit.ly/ea8231-study

Have you had surgery for squamous cell carcinoma of the head and neck (#HNSCC) that has come back? If so, you may be able to participate in this study of a potential new treatment. Learn more: bit.ly/ea3191-study #HeadAndNeckCancer #HNCA

#ClinicalTrial EA7222, led by @immunosarc of @LurieCancer, is a randomized phase 3 trial of doxorubicin alone or in combination w/ pembrolizumab for patients w/ advanced soft tissue #sarcoma & related poorly differentiated sarcomas that are unresectable. bit.ly/EA7222

Do you have early-stage #melanoma and are age 75 or older? If so, you may be eligible to participate in this study of a potential new treatment approach. More info: bit.ly/ea6244-study #SkinCancer #MelanomaResearch

Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH